Key Highlights
- Renalytix (LSE:RENX) has issued a run of announcements headed "Holding(s) in Company" this week, the standard title under which a company passes on a TR-1 notification from a Shareholder whose interest has crossed a disclosable threshold. Read individually, they tell three quite different stories.
- Dilution is the immediate risk: the share count has expanded materially at 6p, and the second Tranche will expand it further. Liquidity is thin.
- Dilution is the immediate risk: the share count has expanded materially at 6p, and the second tranche will expand it further.
Three Notifications, Three Different Stories
Renalytix (LSE:RENX) has issued a run of announcements headed "Holding(s) in Company" this week, the standard title under which a company passes on a TR-1 notification from a shareholder whose interest has crossed a disclosable threshold. Read individually, they tell three quite different stories.
Heights Capital Management, Inc., notifying through CVI Investments, Inc., raised its interest from 8.995% to 15.638%, or 94,431,274 voting rights, on 8 September. The reason given was an Acquisition or disposal of voting rights. That makes it comfortably the largest disclosed holder on the register.
Aberdeen Group plc came in from below the 5% disclosure threshold to 9.848687%, equivalent to 59,469,395 voting rights, also dated 8 September. The holding is managed on behalf of discretionary Investment management clients through abrdn Holdings Limited and abrdn Inc.
UBS Group AG, notifying through UBS AG, moved the other way, from 7.146860% to 5.172495%, holding 31,233,113 voting rights. The reason stated was an event changing the breakdown of voting rights and an increase in the total number of voting rights. That is passive dilution, not selling: UBS crossed a threshold downwards because the denominator grew.
Why the Register Moved
The trigger for all three was the same corporate action. Renalytix announced a proposed fundraise on 1 September and the result on 3 September: a placing of and subscription for 168,366,151 new ordinary shares at 6p each.
The first tranche of 166,811,996 shares was admitted to AIM on 8 September. It comprised 109,082,255 placing shares and 57,729,741 conversion shares issued to Heights Capital as part of a debt-to-equity conversion, which explains that holder's sharp increase. A second tranche of up to 78,042,948 shares is expected to be admitted on or around 29 September, subject to shareholder approval.
A WRAP retail offer for up to £1,000,000 followed on 3 September and closed early. It raised £380,142.12 through 6,335,707 shares at the same 6p price. Total gross proceeds from the fundraise are approximately £10.5 million, of which around £3.9 million is conditional on shareholders passing the necessary resolutions. The company posted a circular and notice of Annual General Meeting on 8 September.
Where Renalytix Is Quoted
One detail deserves emphasis. Renalytix is quoted on AIM, the London Stock Exchange's growth market, under the code RENX. It is not a Main Market company and is not a constituent of the FTSE indices. Its existing ordinary shares resumed trading on AIM at 7.30am on 8 September, alongside admission of the first tranche shares, after being suspended during the cash call.
The Underlying Business
Renalytix is a diagnostics company built around kidney disease. Its lead product, kidneyintelX.dkd, is a blood-based prognostic test for adults with type 2 diabetes and early-stage chronic kidney disease, identifying those at highest risk of rapid decline in kidney function. The company describes it as the first and only test to have received both US Food and Drug Administration authorisation and Medicare reimbursement for that purpose.
On 1 September the company announced a multi-year collaboration with Quest Diagnostics to distribute the test across the United States through Quest's network. Physician ordering is expected to become available in the first quarter of 2027, and the agreement includes an option for Quest to in-license the test on achieving commercialisation milestones. No financial terms were disclosed.
What the Disclosures Do and Do Not Tell You
Taken together, the notifications confirm ownership has been reshaped by the issue of new equity: a converting creditor and an institutional manager stepping up, a bank's percentage falling without any sale. They are disclosures, not valuation signals.
Risks and What Comes Next
Dilution is the immediate risk: the share count has expanded materially at 6p, and the second tranche will expand it further. Liquidity is thin. Cash runway, reimbursement and the pace of adoption through the Quest channel remain the substantive variables. The shareholder meeting, expected around 28 September, is the next scheduled event, with further holdings notifications likely as the register settles.






Please wait processing your request...